You are here: Industry Insights > Otsuka

News List

Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Dise prnewswire
November 01, 2021
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka)...
Otsuka Signs Three-Year Collaboration with Holmusk to Enhance Digital Health and Data Analytics for Global Behavioral Health Programs prnasia
July 08, 2021
Otsuka Pharmaceutical Development & Commercialization, Inc., announces today that it has entered a three-year collaboration with Holmusk Inc., a global data science and digital health company building the world's largest real-world evidence (RWE) ...
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis drugs
June 21, 2021
Akebia today announced that the U.S. Food and Drug Administration accepted for filing the New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.
ERS Genomics signs CRISPR license agreement with Otsuka pharmatimes
March 03, 2021
Dublin-headquartered biotech company ERS Genomics has signed a license agreement with Otsuka for access to CRISPR gene editing technology.
Otsuka Chemical Enters API Business contractpharma
June 19, 2019
Acquires cefixime business from Astellas.
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine and Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) drugs
June 13, 2019
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine and Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML).
Otsuka expects to shell out $120M to settle Avanir's Nuedexta marketing probe fiercepharma
February 24, 2019
Avanir has faced intense scrutiny over its marketing of neurological treatment Nuedexta, and now the company is nearing a deal with the Department of Justice to resolve the government's probe.
Health Canada Approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder firstwordpharma
February 23, 2019
"Brexpiprazole, is a new option for patients with MDD who require augmentation therapy. Its unique mechanism of action and potential benefits will be a new source of optimism for patients suffering from Depression" said Dr. Diane McIntosh.
Celgene invests in Antengene; Otsuka’s new digital-pill pact; MabSpace-HJB merger fiercepharma
January 10, 2019
China's Antengene has raised $120 million in its second financing round, with a contribution from partner Celgene. Otsuka has signed Click Therapeutics in a digital medicine deal potentially worth $305 million. Chinese firms MabSpace and HJB have merged t
Otsuka, Click Therapeutics to create therapy for mental illness biospectrumasia
January 07, 2019
Otsuka Pharmaceutical Co., Ltd. announces that its U.S. holding company subsidiary Otsuka America, Inc, and Click Therapeutics, Inc. (Click) have signed a collaboration agreement for Otsuka and Click to develop and commercialize。

Previous page 1 2 Next page